IsoRay's Cesium-131 Radiation Therapy Shows Favorable Outcomes In Prostate Cancer

Investigators from the University of Pittsburgh School of Medicine have published a clinical study demonstrating favorable outcomes for localized intermediate-risk prostate cancer patients treated with IsoRay Inc's ISR Cesium-131 brachytherapy known as Cesium Blu.

  • Brachytherapy is a localized internal radiation therapy in which seeds, ribbons, or capsules containing a radiation source are placed in or near the tumor.
  • The study analyzed the outcomes for 335 intermediate-risk prostate cancer patients treated with Cesium-131 brachytherapy.
  • Study patients had significant follow-up time. 
  • The study found that both the "favorable" (147 patients) and "unfavorable" (188 patients) intermediate-risk groups demonstrated excellent biochemical outcomes. 
  • Also See: IsoRay's Cesium-131 And Surgical Resection Shows Promise In Recurrent Head & Neck Cancer.
  • Those outcomes were 97.6% and 91.4%, respectively, at five years. For 135 "favorable" patients treated with Cesium-131 implant alone, the outcome was 98.1%.
  • Investigators used Cesium-131 to decrease the duration of acute toxicity compared to other radioisotopes because of its shorter half-life.
  • Price Action: ISR shares are up 6.65% at $0.36 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsprostate cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!